Board Directors with Frequency
Frequency Therapeutics, based in Cambridge, MA, is a company spearheading the movement to restore hearing by harnessing the regenerative potential of progenitor cells in the body, today announced its Board of Directors. Led by Marc A. Cohen of COBRO Ventures as Chairman, members of the Frequency Board were selected for their industry leadership and wealth of management skills to provide a diverse governance team for the company. The Board Members include Tim Barberich, founder and former CEO and Chairman of Sepracor, Inc. (now known as Sunovion), Marc Kozin, Senior Advisor and former President of L.E.K. Consulting, Robert S. Langer, Sc.D., Frequency Co-founder and the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT), and David Lucchino, Frequency Co-founder, President and Chief Executive Officer.
Frequency Therapeutics was founded to translate the breakthrough work in Progenitor Cell Activation (PCA) by its scientific founders, Robert Langer, Sc.D., and Jeff Karp, Ph.D., at the Massachusetts Institute of Technology and Harvard Medical School, into new treatments, where controlled tissue regeneration with locally delivered drugs could have profound therapeutic potential. The company has licensed foundational patents from the Massachusetts Institute of Technology (MIT) and Partners Healthcare. These technologies will be used to advance Frequency’s PCA platform to create disease modifying therapies that activate the body’s dormant abilities to heal, with the lead program focused on small molecules that can reverse chronic noise induced hearing loss.
“Frequency is poised to become a leader in the treatment of chronic hearing loss, a potential $20 billion market with no existing effective therapeutic solutions,” said Marc A. Cohen. “The technologies licensed from MIT and Partners provide a broad platform for Frequency to uncover and activate the regenerative potential of progenitor cells for unprecedented healing benefits in the treatment of hearing loss, eye and skin disorders, gastrointestinal diseases and diabetes.”
“This stellar Board of Directors brings to Frequency a wealth of business acumen and expertise in the biotech and pharmaceutical communities,” said David Lucchino. “We look forward to working with our Board and advisors to grow Frequency into a world-renowned regenerative medicine company.”
Managing Conflict in Organisations: Have you enough of the right kind
Michael O’Neill is a Biotech entrepreneur, currently R&D Director of his own company Inflection Biosciences. He is also a chartered psychologist and has worked as a consultant and technical and organisational issues in the biosciences industry for many years. He is co-editor of the book “A Biotech Manager’s Handbook”, which is a practical guide to some key areas of managing bioscience companies. In this article, he offers some thoughts on how leaders set the tone for the organisational style of their companies and in particular how they manage conflict within the company.
Managing Conflict in Organisations: Part 2
Michael O’Neill is a Biotech entrepreneur, currently R&D Director of his own company Inflection Biosciences. He is also a chartered psychologist and has worked as a consultant and technical and organisational issues in the biosciences industry for many years. He is co-editor of the book “A Biotech Manager’s Handbook”, which is a practical guide to some key areas of managing bioscience companies.
Leadership skills must adapt for rare disease success
In pharmaphorum’s rare disease focus month, Karl Simpson of Liftstream explores whether a different set of skills, experience and talent are required to develop orphan drugs, and questions how different the business model of rare diseases is. The article was originally published in pharmaphorum on 18th February 2014.
Demand Grows for Cancer R&D Executives
Authored by Karl Simpson
David Epstein emerges at newly named Flagship Pioneering
Flagship Pioneering today announced the appointment of industry veteran David Epstein to serve in the newly created role of Executive Partner. Epstein will join as a strategic resource to the firm that systematically conceives, creates, resources and grows first-in-category ventures to transform human health and sustainability. The appointment follows Flagship’s recent additions of industry leaders Dr. Michael Rosenblatt (formerly of Merck) as Chief Medical Officer and Jim Gilbert (formerly of Boston Scientific and Bain) as Senior Partner, and supports the firm’s goal of driving accelerated value growth within its portfolio companies.
“David is a leader and long-time pioneer within the pharma industry, having developed dozens of new medicines benefiting millions of patients around the world,” said Noubar Afeyan, Ph.D., founder and CEO of Flagship. “His progressive approach to science and business acumen gleaned over his tenured career in the pharmaceutical industry complements Flagship’s culture and team. We will apply his expertise broadly as we continue making and realizing the maximum potential of disruptive innovations that yield unprecedented therapies.”
Mr. Epstein’s first significant involvement within the Flagship portfolio will be as Chairman of the Board of Rubius Therapeutics, a venture founded and launched by the Flagship VentureLabs® innovation foundry to exploit the potential medical impact of endowing red blood cells with therapeutic properties. The company’s disruptive platform provides off-the-shelf, enucleated cell-based therapies that promise to treat a wide array of ailments including cancer and autoimmune, metabolic, and hematologic diseases.
“Flagship Pioneering is breaking boundaries and exploring new frontiers that, I believe, could dramatically improve the quality of human life,” said Epstein. “Joining Flagship’s disruptive innovation engine is an opportunity of a lifetime, and I welcome the opportunity to bring my passion for medicine, deep knowledge and ties to industry, and commitment to solving some of the world’s greatest health challenges to bear. In particular, I am tremendously excited by the promise of Rubius’ Red-Cell Therapeutics™ platform, as it portends the broad impact of off-the-shelf, precision cell therapies.”
Do you work in the Massachusetts Life Sciences sector? – Take the Human Capital Pipeline Survey https://www.liftstream.com/pipelinesurvey.html
Chief Medical Officer appointed to Albumedix management
Albumedix A/S announced on January 4th 2017 that it has appointed Dr. Giles Campion as Chief Medical Officer (CMO). Dr Campion brings with him more than 25 years’ experience in drug development from both large pharma and biotech companies having worked in senior development positions in the US as well as Europe.
Shire adds to board with appointment of Ian Clark
Shire plc has joined Agios Pharmaceuticals in announcing the appointment of Ian Clark to the Board of Directors.
Hacked By GeNErAL
Voyager Therapeutics Appoints Jane Pritchett Henderson as Chief Financial Officer
Voyager Therapeutics, a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced the appointment of Jane Pritchett Henderson as senior vice president and chief financial officer effective January 1, 2017. Ms. Henderson brings more than 28 years of life sciences industry and banking experience and leadership to her new role.